Lasa Supergenerics Limited (NSE:LASA)

Market Cap	599.21M
Revenue (ttm)	1.47B
Net Income (ttm)	-147.57M
Shares Out	50.10M
EPS (ttm)	-2.95
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	4,784
Average Volume	184,660
Open	11.96
Previous Close	11.73
Day's Range	11.96 - 11.96
52-Week Range	8.42 - 33.49
Beta	0.17
RSI	48.05
Earnings Date	Aug 12, 2025

About Lasa Supergenerics

Lasa Supergenerics Limited engages in the research, manufacture, and marketing of animal and human healthcare products in India. It offers API products comprising fenbendazole, toldimphos sodium, cyromazine, albendazole, ricobendazole, oxfendazole, closantel base, closantel sodium dihydrate BP, nitroxynil, rafoxanide, oxyclozanide, ornidazole, and halquinol, as well as 2,6-diiodo-4-nitrophenol; and other API products. The company also provides animal feed ingredients, including calcium iodate; and reagents for therapeutic use, such as potassium...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 2016
• Employees: 77
• Stock Exchange: National Stock Exchange of India
• Ticker Symbol: LASA

Financial Performance

In 2024, Lasa Supergenerics's revenue was 1.47 billion, an increase of 41.23% compared to the previous year's 1.04 billion. Losses were -147.57 million, -32.09% less than in 2023.